The 4th Annual Theranostics conference highlights

The 4th Annual Theranostics conference was held about 15 days ago in Melbourne with about 380 participants from all over the world.  This year, the conference focused on the receptor imaging and Peptide Receptor Radionuclide Therapy (PRRT) with the theranostic pair 68Ga & 177Lu for neuroendocrine tumors and prostate cancer.

The PSMA Disruptive Technology session reported the impact in patient management when using this 68Ga-PMSA in prostate cancer patients. “The studies and results with PSMA are now published in high impact journal of oncology and urology” , mentioned prof. Hicks, the host of the conference. There were also some studies on the alpha version of PSMA (with 213Bi and 225Ac) when therapy did not work with 177Lu. The diagnostic 64Cu and therapy 67Cu pair were also presented by the Peter MacCallum Cancer group in collaboration with Clarity Pharmaceuticals. The long-lived 64Cu can be used for prospective dosimetry when using  67Cu for therapy. Other interesting research was presented with Sc-44 and 18F-PSMA.